8-K: Citius Oncology Presents Promising Phase 1 Data for LYMPHIR Combination Therapy

Citius Oncology announced positive Phase 1 clinical data for LYMPHIR in combination with pembrolizumab for recurrent or refractory gynecologic malignancies, showing durable responses and manageable tolerability.

Summary

• Citius Oncology's subsidiary, Citius Oncology, Inc., presented Phase 1 clinical data at the American Society of Clinical Oncology (ASCO) Annual Meeting on May 30, 2026.
• The data evaluated LYMPHIR (denileukin diftitox-cxdl) in combination with pembrolizumab in patients with recurrent or refractory gynecologic malignancies.
• The study involved 25 heavily pre-treated patients, with 21 evaluable for efficacy, who had received a median of five prior therapies.
• Key findings included a 24% Overall Response Rate (ORR) among efficacy-evaluable patients, with a median duration of response not yet reached.
• Notably, 48% of efficacy-evaluable patients achieved clinical benefit, defined as complete response, partial response, or durable stable disease lasting at least six months.
• Median progression-free survival (mPFS) was 20.5 months for patients achieving clinical benefit and 5.8 months overall.
• A single case of reversible Grade 3 capillary leak syndrome (CLS) was observed at the highest dose level, with no maximum tolerated dose achieved.
• A Phase 2 expansion study is planned to further evaluate this combination therapy.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the encouraging clinical signals and manageable safety profile in a challenging patient population, supporting further development.

Positives

• Demonstrated durable responses in heavily pre-treated patients with recurrent or refractory gynecologic malignancies.
• Achieved a 24% Overall Response Rate (ORR) in efficacy-evaluable patients.
• 48% of efficacy-evaluable patients achieved clinical benefit (CR, PR, or durable stable disease > 6 months).
• Median progression-free survival (mPFS) of 20.5 months for patients achieving clinical benefit.
• Observed a 33% ORR in endometrial cancer patients previously treated with checkpoint inhibitors, with one ongoing response over three years.
• The combination therapy showed a manageable tolerability profile.
• No new safety signals or Grade 3 or greater immune-related adverse events were observed.
• The study supports continued clinical evaluation of this chemo-free immunomodulatory approach.

Negatives

• The study was a Phase 1, dose-escalation, investigator-initiated study and not designed or powered to evaluate clinical efficacy.
• No conclusions can be drawn regarding comparative effectiveness or long-term outcomes from this early-stage data.
• Early-stage clinical data may not be predictive of results from larger or later-stage studies.
• One case of reversible Grade 3 capillary leak syndrome (CLS) was observed at the highest dose level.
• The median progression-free survival (mPFS) across all 21 efficacy-evaluable patients was 5.8 months.
• The company requires substantial additional funds and its ability to raise these funds for at least the next 12 months as a going concern is a risk.

Risks

• The need for substantial additional funds and the ability to raise these funds for at least the next 12 months as a going concern.
• The ability to successfully commercialize LYMPHIR and establish a sustainable revenue stream.
• The ability to regain compliance with Nasdaq's continued listing standards.
• Risks relating to the results of research and development activities, including that early-stage clinical data may not be predictive of results from larger or later-stage studies.
• The potential for serious adverse reactions including capillary leak syndrome, visual impairment, infusion-related reactions, and hepatotoxicity associated with LYMPHIR.
• The potential for LYMPHIR to cause fetal harm when administered to a pregnant woman.
• The potential for male fertility to be compromised by treatment with LYMPHIR.
• The company's reliance on third-party logistics providers, distributors, and specialty pharmacies.

Future Outlook

A Phase 2 expansion study is being planned to further evaluate the combination of LYMPHIR and pembrolizumab in gynecologic cancers, including less heavily pre-treated and prior immunotherapy-exposed patient populations. Ongoing translational studies are evaluating the impact of the combination on regulatory T-cells, immune effector cells, and the tumor microenvironment to help identify potential biomarkers for future development strategies.

Management Comments

• "LYMPHIRs ability to transiently deplete immunosuppressive regulatory T-cells may help address immune resistance in the tumor microenvironment and enhance the effect of checkpoint inhibitors."
• "The encouraging clinical signals and tolerability profile observed in this study support continued clinical evaluation of this chemo-free immunomodulatory approach, especially in tumors where resistance to checkpoint inhibitors remains a significant challenge."
• "Patients with recurrent gynecologic malignancies who progress following immunotherapy often have limited treatment options. The clinical activity observed with denileukin diftitox-cxdl plus pembrolizumab, including durable responses and prolonged disease control in heavily pre-treated patients, is notable."
• "Given the lack of effective salvage treatments for these patients, especially those that have failed prior immune-checkpoint inhibition, the novel combination of LYMPHIR plus pembrolizumab provides a potential viable therapeutic option."
• "Importantly, the safety profile observed was manageable in this heavily pre-treated population, supporting continued evaluation in larger studies."

Industry Context

StockSavvy.ai notes that the presentation of Phase 1 data for LYMPHIR in combination with pembrolizumab aligns with the industry trend of exploring novel immunotherapy combinations to overcome resistance to existing treatments, particularly in difficult-to-treat gynecologic cancers. The focus on targeting immunosuppressive regulatory T-cells is a key area of research in immuno-oncology.

Comparison to Industry Standards

• The observed 24% Overall Response Rate (ORR) in a heavily pre-treated population with recurrent or refractory gynecologic malignancies is a notable signal, especially given the limited treatment options for these patients.
• The median progression-free survival (mPFS) of 5.8 months for all efficacy-evaluable patients and 20.5 months for those achieving clinical benefit provides a benchmark for comparison with other investigational therapies in this setting.
• The 33% ORR in a specific subgroup (endometrial cancer patients previously treated with checkpoint inhibitors) is particularly encouraging and warrants further investigation, as responses to checkpoint inhibitors in this population can be challenging.
• The safety profile, including a single case of reversible Grade 3 capillary leak syndrome, appears manageable in the context of heavily pre-treated patients, which is a critical consideration for new combination therapies.

Stakeholder Impact

• Shareholders may see increased interest due to promising early-stage clinical data, potentially impacting stock price, but also face risks related to the company's financial stability and need for future funding.
• Patients with recurrent or refractory gynecologic malignancies may benefit from potential new treatment options if the combination therapy proves successful in later-stage trials.
• Healthcare providers will be interested in the evolving data for LYMPHIR in combination therapy, which could influence treatment decisions for eligible patients.
• Payers will monitor the development of this combination therapy, considering its potential efficacy, safety, and cost-effectiveness in the future.

Next Steps

• A Phase 2 expansion study is being planned to further evaluate the combination in gynecologic cancers.
• Ongoing translational studies are evaluating the impact of the combination on regulatory T-cells, immune effector cells, and the tumor microenvironment to identify potential biomarkers.
• Continued clinical evaluation of this chemo-free immunomodulatory approach is supported by the observed data.

Key Dates

Recommendation

The early-stage positive data for LYMPHIR in combination therapy is encouraging, but the company faces significant financial risks and the results are preliminary. Further data from Phase 2 studies and clarity on funding are needed before a stronger recommendation can be made. Therefore, a 'hold' position is appropriate, allowing investors to monitor developments.

Keywords

LYMPHIR, denileukin diftitox-cxdl, pembrolizumab, gynecologic malignancies, oncology, clinical trial, ASCO, immunotherapy